Eszopiclone in the Treatment of Insomnia and Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Eszopiclone in the Treatment of Insomnia and Associated Symptoms of Fibromyalgia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00392041
• Other study ID #: 0220060122
• Status: Completed
• Phase: Phase 4
• Start date: August 2006
• Est. completion date: March 2009

Study information

• Verified date: December 2020
• Source: Rutgers, The State University of New Jersey
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia. It is hypothesized that participants receiving eszopiclone will report greater improvement in total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than will those receiving placebo.

Description:

Fibromyalgia (FM) is a prevalent, debilitating, and costly syndrome. Although the pathophysiology of FM is not yet well-understood, sleep disturbance is a prominent feature of most theories. Eszopiclone has been approved by the FDA for the treatment of insomnia, but has not been studied in the treatment of FMS. The purpose is to assess the efficacy of eszopiclone for the treatment of insomnia and other symptoms of fibromyalgia (FMS) in FMS patients. Participants will be randomly selected to receive eszopiclone or placebo. It is hypothesized that participants receiving eszopiclone will report greater improvement in total sleep time, sleep quality, pain, fatigue, physical functioning, and emotional distress than will those receiving placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Male or female, age 18 through 64.

2. Meets ACR criteria for FMS, as determined by rheumatological examination and a medical history review.

3. Reports sleep maintenance insomnia (total sleep time of < 6.5 hours or sleep impairment consisting of 3 of 7 nights per week for a month by history) or sleep onset latency insomnia (at least 3 of 7 nights of sleep latency > 30 minutes), as well as clinically significant daytime distress or impairment during the 1 week self assessment prior to baseline.

4. Has completed 8th grade and is fluent in English.

5. If a female of child bearing potential, the patient must be non-pregnant and either post-menopausal or using an approved birth control method. Acceptable birth control methods include: history of tubal ligation, having a male partner who is sterile, IUDs, birth control pills or other hormonal birth control methods (e.g., birth control patch, Depo-Provera injections), and double-barrier methods (e.g., condom and foam).

6. Antidepressant medication will be allowed if the patient has been on a stable dose for at least one month.

Exclusion Criteria:

1. Evidence of traumatic injury, inflammatory rheumatic disease, or infectious or endocrine-related arthropathy.

2. Evidence of a primary sleep disorder (e.g., significant sleep disordered breathing (central or obstructive apnea), periodic limb movement disorder, or REM sleep behavior disorder.

3. Any current, clinically significant medical condition.

4. Pregnancy.

5. Meets DSM-IV criteria for bipolar disorder, psychotic disorder, organic brain syndrome, or psychoactive substance abuse or dependence.

6. Any current psychiatric disorder that would interfere with study participation (investigator judgment).

7. Active suicidal ideation.

8. Plans to engage in additional psychotherapy during the study.

9. Concurrent use of benzodiazepines after 6pm or as a sleep aid.

10. Concurrent use of any other sleep aid.

11. Concurrent use of analgesics other than acetaminophen or non-steroidal anti-inflammatory medication.

12. Concurrent use of any medication that has not been stabilized for at least 1 month prior to screening.

Related Conditions & MeSH terms

• Fibromyalgia
• Insomnia
• Myofascial Pain Syndromes
• Sleep Initiation and Maintenance Disorders

Intervention

Drug:
• Eszopiclone
3mg qpm for 12 weeks
• placebo
1 pill qpm for 12 weeks

Locations

Country	Name	City	State
United States	Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School	Piscataway	New Jersey

Sponsors (2)

Lead Sponsor	Collaborator
Lesley A. Allen, Ph.D.	Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Total Sleep Time (TST) as Recorded in Patient Diaries	Difference in total sleep time between week 4 and baseline	week 4
Secondary	Wake Time After Sleep Onset (WASO)	Minutes awake after sleep onset as recorded in patient diaries	week 12
Secondary	Sleep Quality		week 12
Secondary	Clinician-rated Overall Severity of Fibromyalgia		week 12
Secondary	Fibromyalgia Impact Questionnaire		week 12